Maris JM - Search Results

1

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program.

Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Maris JM, et al. Pediatr Blood Cancer. 2008 Jul;51(1):42-8. doi: 10.1002/pbc.21535. Pediatr Blood Cancer. 2008. PMID: 18293383

2

Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.

Shusterman S, Grupp SA, Maris JM. Shusterman S, et al. Among authors: maris jm. Med Pediatr Oncol. 2000 Dec;35(6):673-6. doi: 10.1002/1096-911x(20001201)35:6<673::aid-mpo41>3.0.co;2-o. Med Pediatr Oncol. 2000. PMID: 11107144

3

Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.

Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Thompson PM, et al. Among authors: maris jm. Cancer Res. 2001 Jan 15;61(2):679-86. Cancer Res. 2001. PMID: 11212268

4

The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.

Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. Shusterman S, et al. Among authors: maris jm. Clin Cancer Res. 2001 Apr;7(4):977-84. Clin Cancer Res. 2001. PMID: 11309349

5

Detailed molecular analysis of 1p36 in neuroblastoma.

White PS, Thompson PM, Seifried BA, Sulman EP, Jensen SJ, Guo C, Maris JM, Hogarty MD, Allen C, Biegel JA, Matise TC, Gregory SG, Reynolds CP, Brodeur GM. White PS, et al. Among authors: maris jm. Med Pediatr Oncol. 2001 Jan;36(1):37-41. doi: 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L. Med Pediatr Oncol. 2001. PMID: 11464901

6

Testing of new agents in childhood cancer preclinical models: meeting summary.

Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Houghton PJ, et al. Among authors: maris jm. Clin Cancer Res. 2002 Dec;8(12):3646-57. Clin Cancer Res. 2002. PMID: 12473573

7

Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.

Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J, Maris JM, Shusterman S. Morowitz MJ, et al. Among authors: maris jm. Clin Cancer Res. 2005 Apr 1;11(7):2680-5. doi: 10.1158/1078-0432.CCR-04-1917. Clin Cancer Res. 2005. PMID: 15814649

8

Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. London WB, et al. Among authors: maris jm. J Clin Oncol. 2005 Sep 20;23(27):6459-65. doi: 10.1200/JCO.2005.05.571. Epub 2005 Aug 22. J Clin Oncol. 2005. PMID: 16116153

9

How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.

Maris JM. Maris JM. Pediatr Blood Cancer. 2005 Dec;45(7):869-70. doi: 10.1002/pbc.20576. Pediatr Blood Cancer. 2005. PMID: 16206200 No abstract available.

10

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM. Matthay KK, et al. Among authors: maris jm. J Clin Oncol. 2006 Jan 20;24(3):500-6. doi: 10.1200/JCO.2005.03.6400. J Clin Oncol. 2006. PMID: 16421427 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

457 results

Search Page